Welcome to our dedicated page for Fosun Internatio news (Ticker: FOSUY), a resource for investors and traders seeking the latest updates and insights on Fosun Internatio stock.
News about Fosun International Limited (FOSUY) covers a broad range of topics reflecting its activities as a global innovation-driven consumer group. Company announcements and media releases describe developments across pharmaceuticals and healthcare, cultural tourism and consumption, financial services, and insurance, as well as updates on its innovation and globalization strategy.
Investors and observers can find news on Fosun’s pharmaceutical and healthcare initiatives, including progress in innovative drugs, medical devices, and healthcare services under entities such as Fosun Pharma and Henlius. Releases highlight clinical and regulatory milestones, new therapeutic indications, and the use of artificial intelligence in areas such as drug development decision-making and clinical trial prediction.
Coverage also includes cultural tourism and consumption news, such as performance and expansion of Club Med resorts under Fosun Tourism Group, cultural events, and consumer-focused projects. In financial services and insurance, news items discuss developments at Fosun Insurance Portugal (Fidelidade), asset servicing activities in Europe, and strategic portfolio adjustments, including asset sales and retained businesses.
Another important theme in Fosun-related news is ESG and sustainability. Articles describe its ESG ratings, inclusion in sustainability indices and yearbooks, climate disclosure practices, and social responsibility programs such as the Rural Doctors Program and contributions to global malaria treatment. Governance and award recognitions, including honors from organizations like Corporate Governance Asia, also feature prominently.
For those following FOSUY, this news stream provides insight into how Fosun advances its stated strategy of "Innovation + Globalization", how its core subsidiaries perform, and how it integrates ESG considerations into its operations. Regularly reviewing these updates can help readers understand the group’s evolving business focus and corporate priorities.
Fosun International (FOSUY) reported its 2024 annual results with total revenue of RMB192.14 billion and industrial operation profit of RMB4.9 billion. The company's four core subsidiaries generated RMB134.65 billion, representing 70.1% of total revenue.
Key financial metrics include:
- Total debt to capital ratio: 52%
- Cash and bank balance: RMB106.34 billion
- Overseas revenue: 49.3% (up 6.2% YoY)
- Technology innovation investment: RMB6.9 billion
The Group reported a loss attributable to owners of RMB4.35 billion, primarily due to a one-off non-cash loss. Excluding this effect, profit was RMB0.75 billion. The company completed asset divestments worth RMB17.5 billion at group level and RMB30.0 billion at consolidated level. In November 2024, Fosun successfully returned to the offshore USD bond market and maintained its BB- credit rating with stable outlook from S&P.
Fosun International (FOSUY) has successfully refinanced a USD 870 million equivalent syndicated loan due March 28, 2025. The refinancing includes a new USD 675 million three-year sustainability-linked syndicated loan, jointly led by major Chinese and international banks.
The new loan, representing the largest syndicated loan for a Chinese private enterprise this year, was led by Bank of China, China Construction Bank, Bank of Communications, BNP Paribas, Commerzbank, HSBC, MUFG, and Standard Chartered. The deal includes a greenshoe option for additional bank participation.
Additionally, Fosun High Technology, a wholly-owned subsidiary, secured a RMB 1.23 billion three-year syndicated loan in China. The company also successfully resumed USD bond issuances in November 2024 and January 2025, demonstrating its progress in diversifying financing channels.
Fosun International Chairman Guo Guangchang addressed the 25th Annual Conference of Yabuli China Entrepreneurs Forum, emphasizing that private enterprises thrive with fair competition opportunities and commitment to product excellence. Despite economic challenges, Fosun has seen positive consumer response across its portfolio, with high occupancy at Atlantis Sanya, strong sales growth for Shede Spirits, and successful tourism ventures.
Over the past two years, Fosun has strategically divested over RMB80 billion in non-core assets, significantly reducing debt and successfully navigating its "maturity wall." The company is now focusing on its core advantages in health, tourism, and consumption sectors. Recent initiatives include establishing a RMB5.0 billion biomedical industry fund with Shenzhen Municipal Government and advancing tourism projects.
Fosun's global presence spans 35 countries and regions, with notable success in biopharmaceuticals through Shanghai Henlius, which recently launched its PD-1 monoclonal antibody in the European Union. The company is actively integrating AI technology across its business sectors to enhance efficiency and drive innovation.
Fosun International has signed a Memorandum of Strategic Cooperation with the Abu Dhabi Investment Office (ADIO) on February 20, 2025, marking a significant expansion into the Middle East region. The agreement will provide Fosun with tailored investment support, streamlined market access, and strategic resource connections in key sectors including healthcare innovation, wealth management, fintech, tourism, and Hive City projects.
The company has already made notable progress in the Middle East market over the past six months: Roc Oil completed an acquisition of Tethys Oil AB's oilfield blocks in Oman; Henlius entered a strategic collaboration with SVAX in Saudi Arabia; and FFT formed a joint venture with Khaled Juffali Company to provide automated production line solutions for Saudi Arabia's electric vehicle industry.
Fosun International (HKEX: 00656) has been selected for the S&P Global's Sustainability Yearbook 2025 for the second consecutive year, highlighting its strong ESG performance. Out of 7,690 companies assessed across 62 industries, only 780 were selected, with just 10 from the industrial conglomerates sector.
The company achieved a CSA score of 70 in 2024, placing it in the top 5% among global peers and approximately 40 points above the industry average. Fosun has maintained an MSCI ESG rating of AA since 2021 and holds an HSI ESG rating of AA-.
Notable achievements include ranking in the top 1% in S&P Global's Sustainability Yearbook 2024 (China Edition) and recognition as an "Industry Mover". The company's "Rural Doctors Program" was also featured among the UN Global Compact's "20 Cases of Private Sector's Sustainable Development in China for 20 Years" in November 2024.
Fosun International (OTC:FOSUF) and Natixis CIB signed a strategic cooperation agreement on 16 January 2025 to deepen long‑term collaboration across advisory, financing, transaction structuring and risk hedging. Natixis CIB will leverage its international network, boutique M&A expertise, and stable funding to support Fosun and its subsidiaries' development and globalization. Fosun highlighted its global footprint in more than 35 countries and framed the deal as a continuation of a partnership that began in 2010 and strengthened in 2014 and 2018.
The agreement was signed at the Bund Finance Center with senior executives from both parties in attendance, and the press release discloses no financial terms or deal values.
Fosun International (HKEX: 00656) has signed a strategic cooperation agreement with Natixis Corporate & Investment Banking on January 16, 2025. The agreement strengthens their partnership that began in 2010 and was enhanced in 2014. Under the new agreement, Natixis CIB will provide Fosun with consulting and financial services in financing, transaction structuring, and risk hedging, leveraging its expertise in specialized fields and operations in Europe and the Americas.
The agreement was signed at the Bund Finance Center by Zhang Houlin, Senior Vice President and Co-CFO of Fosun International, and Liu Hong, Senior Country Manager, Greater China, Natixis CIB. Fosun, which operates in more than 35 countries, will benefit from Natixis CIB's network and resources to support its global development strategy. Natixis CIB, a subsidiary of French banking group Groupe BPCE, will utilize its high credit ratings and stable funding sources to support this partnership.
Fosun International has achieved a significant milestone in S&P Global's 2024 Corporate Sustainability Assessment (CSA), scoring 70 points and ranking in the top 5% among global peers. This represents an improvement from their previous score of 68 points and top 6% ranking last year, significantly outperforming the industry average of 30 points.
The company received balanced scores across key dimensions: 72 in governance and economic, 68 in environmental, and 71 in social aspects. Notable achievements were recorded in Business Ethics, Environmental Policy, Energy, Climate Strategy, Risk Management, Human Capital Development, and Customer Relationship Management.
Fosun's commitment to ESG is further evidenced by its inclusion in S&P Global's Sustainability Yearbook 2024, its AA rating from MSCI ESG (unique among Greater China conglomerates), and its consistent presence in the FTSE4Good Index Series. The company recently launched its sustainable development strategy 'Create IMPACT' to drive innovation and global sustainability initiatives.
Fosun International has been awarded the prestigious 'Outstanding ESG Award' along with 'Best in ESG Practices' and 'Best in ESG Report' at the TVB ESG Awards ceremony held on December 13, 2024, in Hong Kong. The company, which operates in over 35 countries across healthcare, tourism, consumption, and insurance sectors, was recognized for its comprehensive ESG management system and sustainable development initiatives.
Notable achievements include their commitment to peak carbon emissions by 2028 and achieve carbon neutrality by 2050, the establishment of a Carbon Neutrality Committee, and significant healthcare innovations. Their pharmaceutical division has made breakthrough developments, including Yi Kai Da, the first CAR-T cell therapy approved in mainland China, and artesunate injections that have treated over 72 million severe malaria patients globally.
The company has implemented its 'Create IMPACT' sustainable development strategy, focusing on innovation, mindful operation, people-oriented approach, advanced governance, climate positivity, and transparency.
Atlantis Sanya hosts the 2024 China Mermaid Open Grand Final and Asian Cup on December 12th-13th, marking the first Asian Cup for mermaid sports. Over 70 top athletes from various Asian countries and regions compete at the Ambassador Lagoon, featuring 13,500 tonnes of seawater and an 11-metre-deep open-air setting.
The event, jointly hosted by multiple Chinese sports authorities and Fosun Tourism Group, represents a significant step toward internationalizing mermaid sports. The venue's 16.5-metre-wide, 10-metre-high acrylic viewing panel allows spectators to witness the underwater performances up close.
This marks the fourth consecutive year Atlantis Sanya has hosted the Mermaid Open, contributing to Hainan's development as a sports tourism destination and supporting China's national sports development strategies.